Table 4 Availability of brand name and generic orphan drugs surveyed in 24 public tertiary hospitals in China
From: The availability and affordability of orphan drugs for rare diseases in China
Availability | Range | Originator Brands (Brand Name) | Generics |
|---|---|---|---|
Absent | 0 | Ambrisentan (Volibris), Somatropin (Genotropin), Dasatinib (Sprycel), Meisoindigo | None |
Very low | <30Â % | Imiglucerase (Cerezyme), Sapropterin dihydrochloride (Kuvan), Coagulation factor VIIa (Novoseven), Bosentan (Tracleer), Iloprost (Ventavis), Somatropin (Saizen), Somatropin (Humatrope), Busulfan(Busulfex), Imatinib Mesylate Cap (Glivec), Nilotinib (Tasigna), Riluzole ( Rilutek) | Teniposide, Riluzole taba, Riluzole capa |
Low | 30–49 % | Recombinant coagulation factor VIII (Kogenate FS), Imatinib mesylate Tab (Glivec), Arsenious acid(Yitaida), Sorafenib (Nexavar) | Human coagulation factor VIII, Danazol |
Fairly high | 50–80 % | Teniposide (Vumon), Rituximab (MabThera), Poractant alfa (Curosurf) | Human prothrombin complex concentrate, Recombinant human growth hormone, Mitoxantrone, Homoharringtonine |
High | 80Â % | None | None |